114926-41-9

Basic information

• Product Name: BOC-5-FLUORO-D-TRYPTOPHAN
• Synonyms: BOC-5-FLUORO-D-TRYPTOPHAN;(R)-2-(N-(Tert-Butoxy)Carbonyl Amino)-3-(5-fluoroindol-3-yl)propanoic acid;Cbz-D-5-fluoroTryptophan
• CAS NO: 114926-41-9
• Molecular Formula: C16H19FN2O4
• Molecular Weight: 322.33
• Mol File: 114926-41-9.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 538.3±50.0 °C(Predicted)
• Appearance: /
• Density: 1.314±0.06 g/cm3(Predicted)
• PKA: 3.82±0.10(Predicted)
• CAS DataBase Reference: BOC-5-FLUORO-D-TRYPTOPHAN(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-5-FLUORO-D-TRYPTOPHAN(114926-41-9)
• EPA Substance Registry System: BOC-5-FLUORO-D-TRYPTOPHAN(114926-41-9)

Safety Data

• Hazardous Substances Data: 114926-41-9(Hazardous Substances Data)

Usage

General Description

BOC-5-FLUORO-D-TRYPTOPHAN is a synthetic compound derived from the amino acid tryptophan. It is a derivative of tryptophan that contains a protective Boc (tert-butoxycarbonyl) group and a fluorine atom at the 5 position. BOC-5-FLUORO-D-TRYPTOPHAN is often used in chemical research and drug development due to its potential as a building block for designing new pharmaceuticals and understanding protein-ligand interactions. BOC-5-FLUORO-D-TRYPTOPHAN may have applications in the development of novel drugs, particularly in the area of serotonin receptor modulation and antimicrobial activity. Additionally, its unique structure and properties make it an important tool for studying the structure-function relationship of tryptophan-containing proteins and peptides.

Upstream product

• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 154-08-5 DL-5-fluorotryptophan 
• 24424-99-5 di-tert-butyl dicarbonate 
• 343-90-8 3-dimethylaminomethyl-5-fluoroindole 
• 16626-02-1 5-fluoro-L-tryptophan 
• 908846-88-8 (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(5-fluoro-1H-indol-3-yl)-propanoic acid 

Downstream Products

• 1234870-95-1 t-butoxycarbonyl-DL-6-fluorotryptophan 
• 16626-02-1 5-fluoro-L-tryptophan 

Relevant articles and documents

PCSK9 ANTAGONIST COMPOUNDS

Disclosed are compounds of Formula (A), or a pharmaceutically acceptable salt thereof: where A, X, R1, and R2 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula (I) or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.

A class of DL-tryptophan compounds, preparation method and applications thereof

The invention provides a DL-tryptophan compound represented by a general formula I or a pharmaceutically acceptable salt thereof, a preparation method and applications thereof, especially applicationsin preparation of RANKL inhibitors. According to the DL-tryptophan compound or the pharmaceutically acceptable salt thereof, an OPG-RANKL-RANK signal system can be intervened by inhibiting the interaction of RANKL-RANK, and the activity of RANKL in osteoclast precursor cells is regulated and controlled, so that formation of osteoclasts is inhibited, and bone resorption is reduced; and the DL-tryptophan compound or the pharmaceutically acceptable salt thereof is expected to play a role in preventing and treating bone metabolic diseases, and brings good news to bone metabolic disease patients.

Development of Small-Molecules Targeting Receptor Activator of Nuclear Factor-κB Ligand (RANKL) - Receptor Activator of Nuclear Factor-κB (RANK) Protein-Protein Interaction by Structure-Based Virtual Screening and Hit Optimization

Targeting RANKL/RANK offers the possibility of developing novel therapeutic approaches to treat bone metabolic diseases. Multiple efforts have been made to inhibit RANKL. For example, marketed monoclonal antibody drug Denosumab could inhibit the maturation of osteoclasts by binding to RANKL. This study is an original approach aimed at discovering small-molecule inhibitors impeding RANKL/RANK protein interaction. We identified compound 34 as a potent and selective RANKL/RANK inhibitor by performing structure-based virtual screening and hit optimization. Disruption of the RANKL/RANK interaction by 34 effectively inhibits RANKL-induced osteoclastogenesis and bone resorption. The expression of osteoclast marker genes was also suppressed by treatment of 34. Furthermore, 34 markedly blocked the NFATc1/c-fos pathway. Thus, our current work demonstrates that the chemical tractability of the difficult PPI (RANKL/RANK) target by a small-molecule compound 34 offers a potential lead compound to facilitate the development of new medications for bone-related diseases.